REC-3964 not checked
Recursion Pharmaceuticals Inc.
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “REC-3964 given at a dose of either 500 mg q12h or 250 mg q12h”In the company’s words, NCT06536465 on ClinicalTrials.gov
- Main trialPhase 2
- “This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).”In the company’s words, NCT06536465 on ClinicalTrials.gov
Other drugs for Recurrent Clostridioides Difficile Infection
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Terminated | 6 May 2025 | The Clostridioides Difficile Trial of REC-3964 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026